+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Stiolto"

COPD in the United States: Understanding the COPD Patient Experience - Product Thumbnail Image

COPD in the United States: Understanding the COPD Patient Experience

  • Report
  • January 2024
  • 156 Pages
  • United States
COPD in the United States: Key Insights into Treatment Awareness & Satisfaction - Product Thumbnail Image

COPD in the United States: Key Insights into Treatment Awareness & Satisfaction

  • Report
  • January 2024
  • 114 Pages
  • United States
Emphysema Treatment Market by Medication Type, Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031 - Product Thumbnail Image

Emphysema Treatment Market by Medication Type, Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031

  • Report
  • December 2022
  • 210 Pages
  • Global
From
  • 3 Results (Page 1 of 1)
Loading Indicator

Stiolto is a brand of respiratory drugs used to treat chronic obstructive pulmonary disease (COPD). It is a combination of two drugs, tiotropium and olodaterol, which work together to reduce symptoms of COPD such as shortness of breath and wheezing. Stiolto is taken as an inhaler and is available in both a standard and a Respimat inhaler. The Respimat inhaler is designed to deliver a slow, steady dose of the drug over a longer period of time. Stiolto is a relatively new drug on the market, but it has quickly become a popular choice for treating COPD. It is generally well-tolerated and has been shown to improve lung function and reduce COPD symptoms. Companies in the Stiolto market include Boehringer Ingelheim, GlaxoSmithKline, and AstraZeneca. Show Less Read more